



Identifying a Trial Population for Clinical Studies on Diabetes Drug Testing with Neural Networks

Tim Löhr

Supervisor: Philipp Schlieper

Machine Learning and Data Analytics for Industry 4.0

Final Presentation

Machine Learning and Data Analytics (MaD) Lab

Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)

July 15, 2020



Motivation



Use more
Machine Learning
in **Medicine**.

To save more **lives**.

Figure 1. AI <https://www.hhmglobal.com/industry-updates/press-releases/artificial-intelligence-ai-medicine-in-a-block-chain-device>

Pave the way



The new
Electronic Patient File
coming into force
on 1.1.2021




Jens Spahn
German Minister
of **Health**

Figure 2. EHR <https://de.cleanpng.com/png-chs524/download-png.html>

Figure 3. Jens Spahn https://www.jens-spahn.de/hubfs/Jens_Spahn_08_breit.jpeg

Electronic Health Records



Central storage of healthcare encounters

Why?

- (1) Discover novel disease treatments
- (2) Improve patients diagnosis
- (3) Improve personalized healthcare

Figure 4. Germany eHealth <https://www.krankenkassenzentrale.de/wiki/incoming-en#>

Problem Statement

Find a suitable **target** group of people for a clinical trial test of novel **Diabetes** drugs or **treatments**



7 Million cases of **Diabetes** in Germany alone [1]

Figure 7. Diabetes <https://www.vectorstock.com/royalty-free-vector/concept-of-diabetes-sugar-vector-18519211>

Figure 8. Population <https://freessvg.org/vector-image-of-population-icon>

[1] https://www.diabetesde.org/ueber_diabetes/was_ist_diabetes/_diabetes_in_zahlen

Related Work

Overview of artificial intelligence in medicine

Amisha¹, Paras Malik¹, Monika Pathania¹, Vyas Kumar Rathaur²

¹Department of Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, ²Department of Paediatrics, Government Doon Medical College, Dehradun, Uttarakhand, India

Evaluating predictive modeling algorithms to assess patient eligibility for clinical trials from routine data



Felix Köpcke^{1*}, Dorota Lubgan², Rainer Fietkau², Axel Scholler³, Carla Nau³, Michael Stürzl⁴, Roland Croner⁵, Hans-Ulrich Prokosch¹ and Dennis Toddenroth¹

Artificial Intelligence Applications in Type 2 Diabetes Mellitus Care: Focus on Machine Learning Methods

Shahabeddin Abhari¹, Sharareh R. Niakan Kalhori¹, Mehdi Ebrahimi^{2,3}, Hajar Hasannejadasl¹, Ali Garavand⁴

[2] AI in Medicine <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691444/> 2019

[3] Patient Selection <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029400/pdf/1472-6947-13-134.pdf> 2013

[4] AI against Diabetes <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859270/pdf/hir-25-248.pdf> 2020

Research Question

Can **Machine Learning** be safely applied in the real clinical environment if it just provides enough **explainability** for its predictions?



- (1) How many metrics are enough?
- (2) Does a combination of metrics improve the overall explainability?

Figure 9. EKG <https://wtig.org/wissensdatenbank/ki/explainable-artificial-intelligence-xai-wenn-sich-ki-selbst-erklaeren-muss/>

Methods

- (1) Model a Neural Network with TensorFlow
- (2) Explain the model (*why*)
with Uncertainty Estimation and Metrics
- (3) Explain the predictions (*how*)
with SHAP and LIME

Dataset

From **UCI Machine Learning Repository** [5]

- Collected 1999-2008 in the USA
- Originally 101766 **Samples** and 50 **Features**

Medication codes from the official **FDA** website [6]:

- Different company, same drug
where NDC Code: 71619-388-60 = Glipzide
and NDC Code: 71619-388-73 = Glipzide

Diagnosis codes from the official **ICD** website [7]:



- 250.83 stands for type 1 Diabetes

[5] <https://archive.ics.uci.edu/ml/datasets/diabetes>

[6] <https://www.accessdata.fda.gov>

[7] <https://icdcodelookup.com/icd-10/>

Dataset Distribution



Evaluation – Model



- (1) Aleatoric Uncertainty
natural
- (2) Epistemic Uncertainty
provide more features

Metrics



- (1) Brier score
- (2) AUC score
- (3) F1 score
- (4) Precision score
- (5) Recall Score

Figure 10. Metric SVG https://www.flaticon.com/free-icon/statistics_2004886?term=metrics&page=1&position=24

Evaluation – Predictions






Figure 11. XAI <https://codete.com/blog/explainable-ai/>

Results – Model Accuracy



(1) Brier Score:	0.335
(2) AUC Score:	0.667
(3) F1 Score:	0.661
(4) Precision Score	0.664
(5) Recall Score:	0.664

Results – Model Accuracy




(1) Brier Score:	0.594
(2) AUC Score:	0.635
(3) F1 Score:	0.577
(4) Precision Score	0.405
(5) Recall Score:	0.405

Results – With different boundaries

Ethnicity FPR

1 week


FPR DISPARITY (ETHNICITY)



Not labeled above:
A: Hispanic, 0.87

5 days


FPR DISPARITY (ETHNICITY)



Not labeled above:
A: Hispanic, 0.80

3 days

FPR DISPARITY (ETHNICITY)




Not labeled above:
A: Hispanic, 0.80

Results – Uncertainty Estimation


Gender Disparity

TPR DISPARITY (GENDER)




Not labeled above:
A: Unknown/Invalid, -1.71

FPR DISPARITY (GENDER)



Not labeled above:
A: Unknown/Invalid, 0.00

TNR DISPARITY (GENDER)




Not labeled above:
A: Unknown/Invalid, 1.28

Results – Uncertainty Estimation


Ethnicity Disparity

FPR DISPARITY (RACE)




Not labeled above:
A: Hispanic, 0.58

TNR DISPARITY (RACE)




Not labeled above:
A: Hispanic, 1.14

TPR DISPARITY (RACE)





Not labeled above:
A: Hispanic, 0.89

Results – Uncertainty Estimation



Results – LIME

Real Label: 7



Feature	Value
discharge_disposition_id_1	0.00
admission_source_id_5	0.00
admission_source_id_4	0.00
max_glu_serum_>300	0.00
drug_name_Miglitol	0.00
discharge_disposition_id_15	0.00
admission_source_id_10	0.00
drug_name_Metformin Rosiglitazone	0.00
discharge_disposition_id_27	0.00

Discharge Disposition ID

- discharge_disposition_id_1: Discharged to home
- discharge_disposition_id_15: 'Discharged/transferred within this institution to Medicare approved swing bed'
- discharge_disposition_id_27: NaN
- discharge_disposition_id_6: Discharged/transferred to home with home health service**

Admission Source ID




- admission_source_id_5: Transfer from a Skilled Nursing Facility (SNF)
- admission_source_id_4: Transfer from a hospital
- admission_source_id_10: Transfer from critical access hospital
- admission_source_id_17: NaN**

Admission Type ID




- admission_type_id_1: Emergency**

race_Caucasian	1
gender_Female	1
age_[70-80)	1
admission_type_id_1	1
discharge_disposition_id_6	1
admission_source_id_17	1
max_glu_serum_>300	1
change_Ch	1
readmitted_NO	1
drug_name_Rosiglitazone	1

Results – Shapely



Results – Shapely



Discussion

With just enough **explainability**,
can **Machine Learning** be applied in the Industry 4.0?

Pros:

- (1) Support for doctor's decision
- (2) Patient selection saves a lot of time
- (3) Possible new insights

Cons:

- (1) Unstructured data
- (2) Can it also be applied for other EHR data?
- (3) Necessary needed data amount unclear

Conclusion

(1) Apply it without additional doctor's approval?

For sure not. What if only one person dies because of a false decision of the Machine Learning model?

(2) Apply it as a support technology?

Sure if a doctor validates the result it can be used to support the clinical trials.

Future Work

- (1) Try different XAI methods
- (2) Try different classifiers:
Use GPU to train XGBoost -> better results?
- (3) Epistemic Uncertainty:
Different Neural Network Layers:
tfp.layers.DenseVariational

Thanks for listening

